Advancing Clinical Decision Making by Reverse Translating Tumor & T-Cell Biomarker Signals Into Actionable TIL Response Frameworks

  • Leveraging PD-1-positive TIL selection strategies as surrogate biomarkers of tumor reactivity in breast cancer solid tumor
  • Correlating TCR clonal expansion dynamics with multiomic translational datasets to identify predictive biomarkers of response
  • Building translational workflows to integrate TCR sequencing, tumor biology, and patient response data for next-generation TIL and TCR-T development